1. Li Y, Kumar S, Zhang L. Mechanisms of antibiotic resistance and developments in therapeutic strategies to combat Klebsiella pneumoniae infection. Infect Drug Resist. 2024; 17: 1107-19. [DOI:10.2147/IDR.S453025] [PMID] []

2. Han X, Yao J, He J, Liu H, Jiang Y, Zhao D, et al. Clinical and laboratory insights into the threat of hypervirulent Klebsiella pneumoniae. Int J Antimicrob Agents. 2024; 64 (3):107275. [DOI:10.1016/j.ijantimicag.2024.107275] [PMID]

3. Beig M, Aghamohammad S, Majidzadeh N, Asforooshani MK, Rezaie N, Abed S, et al. Antibiotic resistance rates in hypervirulent Klebsiella pneumoniae strains: a systematic review and meta-analysis. J Glob Antimicrob Resist. 2024; 38: 376-88. [DOI:10.1016/j.jgar.2024.06.018] [PMID]

4. Tang Y, Du P, Du C, Yang P, Shen N, Russo TA, et al. Genomically defined hypervirulent Klebsiella pneumoniae contributed to early-onset increased mortality. Nat Commun. 2025; 16(1): 2096. [DOI:10.1038/s41467-025-57379-4] [PMID] []

5. Liao Y, Gong J, Yuan X, Wang X, Huang Y, Chen X. Virulence factors and carbapenem-resistance mechanisms in hypervirulent Klebsiella pneumoniae. Infect Drug Resist. 2024; 17: 1551-9. [DOI:10.2147/IDR.S461903] [PMID] []

6. Vaez H, Yazdanpour Z. Distribution of virulence‐associated and aminoglycoside resistance genes among clinical isolates of Klebsiella pneumoniae in the southeast of Iran, during 2019-2023: a cross‐sectional study. Health Sci Rep. 2024; 7(12): e70309. [DOI:10.1002/hsr2.70309] [PMID] []

7. Dangor Z, Benson N, Berkley JA, Bielicki J, Bijsma MW, Broad J, et al. Vaccine value profile for Klebsiella pneumoniae. Vaccine. 2024; 42(19): S125-41. [DOI:10.1016/j.vaccine.2024.02.072] [PMID]

8. Lin TL, Yang FL, Ren CT, Pan YJ, Liao KS, Tu IF, et al. Development of Klebsiella pneumoniae capsule polysaccharide-conjugated vaccine candidates using phage depolymerases. Front Immunol. 2022; 13: 843183. [DOI:10.3389/fimmu.2022.843183] [PMID] []

9. Vaez H, Vaez V. Comprehensive analysis of four major surface proteins for vaccine design against Klebsiella pneumoniae. Infect Epidemiol Microb. 2025; 11(1): 1-12 [DOI:10.61186/iem.11.1.1]

10. Douradinha B. Exploring the journey: A comprehensive review of vaccine development against Klebsiella pneumoniae. Microbiol Res. 2024:127837. [DOI:10.1016/j.micres.2024.127837] [PMID]

11. Garnier J. GOR secondary structure prediction method version IV. Meth Enzym RF Doolittle Ed. 1998; 266: 540-53. [DOI:10.1016/S0076-6879(96)66034-0] [PMID]

12. Gasteiger E, Hoogland C, Gattiker A, Duvaud SE, Wilkins MR, Appel RD, et al. Protein identification and analysis tools on the ExPASy server. In: Walker JM, editor. The Proteomics Protocol Handbook. Totowa, NJ: Humana press; 2005. [DOI:10.1385/1-59259-890-0:571]

13. Doytchinova IA, Flower DR. VaxiJen: A server for prediction of protective antigens, tumour antigens, and subunit vaccines. BMC Bioinfo. 2007; 8: 1-7. [DOI:10.1186/1471-2105-8-4] [PMID] []

14. Larsen JE, Lund O, Nielsen M. Improved method for predicting linear B-cell epitopes. Immune Res. 2006; 2: 1-7. [DOI:10.1186/1745-7580-2-1] [PMID] []

15. Chou PY, Fasman GD. Prediction of the secondary structure of proteins from their amino acid sequence. Adv Enzymol Relat Areas Mol Biol. 1979; 47: 45-148. [DOI:10.1002/9780470122921.ch2] [PMID]

16. Karplus PA, Schulz GE. Prediction of chain flexibility in proteins: A tool for the selection of peptide antigens. Naturwissenschaften.1985; 72(4): 212-3. [DOI:10.1007/BF01195768]

17. Emini EA, Hughes JV, Perlow D, Boger J. Induction of hepatitis A virus-neutralizing antibody by a virus-specific synthetic peptide. J Virol.1985; 55(3): 836-9. [DOI:10.1128/jvi.55.3.836-839.1985] [PMID] []

18. Kolaskar AS, Tongaonkar PC. A semi-empirical method for prediction of antigenic determinants on protein antigens. FEBS Lett. 1990; 276(12): 172-4. [DOI:10.1016/0014-5793(90)80535-Q] [PMID]

19. Saha S, Raghava GP. Prediction of continuous comprehensive review of vaccine development B-cell epitopes in an antigen using recurrent neural network. Proteins Struct Funct Bioinf. 2006; 65(1): 40-8. [DOI:10.1002/prot.21078] [PMID]

20. Waterhouse A, Bertoni M, Bienert S, Studer G, Tauriello G, Gumienny R, et al. SWISSMODEL: Homology modelling of protein structures and complexes. Nucleic Acids Res. 2018; 46: 296-303. [DOI:10.1093/nar/gky427] [PMID] []

21. Williams CJ, Headd JJ, Moriarty NW, Prisant MG, Videau LL, Deis LN, et al. MolProbity: More and better reference data for improved all-atom structure validation. Prot Sci. 2018; 27(1): 293315. [DOI:10.1002/pro.3330] [PMID] []

22. Gupta S, Kapoor P, Chaudhary K, Gautam A, Kumar R, In silico approach for predicting toxicity of peptides and proteins. PloS One. 2013; 8(9): e73957. [DOI:10.1371/journal.pone.0073957] [PMID] []

23. Nguyen MN, Krutz NL, Limviphuvadh V, Lopata AL, Gerberick GF, Maurer-Stroh S. AllerCatPro2.0: A web server for predicting protein allergenicity potential. Nucleic Acids Res.

24. 2022; 50: 36-43.

25. Walker JM. The proteomics protocols handbook. Humana press. Springer; 2005. [DOI:10.1385/1592598900]

26. Yan Z, Kim K, Kim H, Ha B, Gambiez A, Bennett J, et al. Next-generation IEDB tools: a platform for epitope prediction and analysis. Nucleic Acids Res. 2024; 52: 526-32. [DOI:10.1093/nar/gkae407] [PMID] []

27. Miller JC, Cross AS, Tennant SM, Baliban SM. Klebsiella pneumoniae lipopolysaccharide as a vaccine target and the role of antibodies in protection from disease. Vaccine. 2024 ;12(10): 1177. [DOI:10.3390/vaccines12101177] [PMID] []

28. Chen Z, Gou Q, Yuan Y, Zhang X, Zhao Z, Liao J, et al. Vaccination with a trivalent Klebsiella pneumoniae vaccine confers protection in a murine model of pneumonia. Vaccine. 2024; 42(23): 126217. [DOI:10.1016/j.vaccine.2024.126217] [PMID]

29. Shamanna V, Srinivas S, Couto N, Nagaraj G, Sajankila SP, Krishnappa HG, et al. Geographical distribution, disease association and diversity of Klebsiella pneumoniae K/L and O antigens in India: roadmap for vaccine development. Microb Genom. 2024; 10(7): 001271. [DOI:10.1099/mgen.0.001271]

30. Li M, Yu M, Yuan Y, Li D, Ye D, Zhao M, et al. Designing a conjugate vaccine targeting Klebsiella pneumoniae ST258 and ST11. Heliyon. 2024; 10(5): 27417. [DOI:10.1016/j.heliyon.2024.e27417] [PMID] []

31. Hakimian M, Doosti A, Sharifzadeh A. A novel chimeric vaccine containing multiple epitopes for simulating robust immune activation against Klebsiella pneumoniae. BMC Immunol. 2024; 25(1): 27. [DOI:10.1186/s12865-024-00617-z] [PMID] []

32. Tajuelo A, Gato E, Oteo-Iglesias J, Pérez-Vázquez M, McConnell MJ, Martín-Galiano AJ, et al. Deep intra clonal analysis for the development of vaccines against drug-resistant Klebsiella pneumoniae lineages. Int J Mole Sci. 2024; 25(18): 9837. [DOI:10.3390/ijms25189837] [PMID] []

33. Illenseher MS, Hentschker C, Gesell Salazar M, Busch LM, Zierke L, Reder A, et al. Global quantitative proteome analysis of a multi-resistant Klebsiella pneumoniae strain. Front Microbiol. 2025; 16: 1528869. [DOI:10.3389/fmicb.2025.1528869] [PMID] []

34. Meekes LM, Heikema AP, Tompa M, Astorga Alsina AL, Hiltemann SD, Stubbs AP, et al. Proteogenomic analysis demonstrates increased bla OXA-48 copy numbers and OmpK36 loss as contributors to carbapenem resistance in Klebsiella pneumoniae. Antimicrob Agents Chemother. 2025; 69 (7): e00107-25.

35. Ranjbar KJ, Sarkoohi P, Shahbazi B, Babaei M, Ahmadi K. Bioinformatics analysis of the in silico engineered protein vaccine with and without Escherichia coli heat-labile enterotoxin adjuvant on the model of Klebsiella pneumoniae. Sci Rep. 2025; 15(1): 7321. [DOI:10.1038/s41598-025-91602-y] [PMID] []

36. Novak P, Havlícek V. Protein extraction and precipitation. proteomic profiling and analytical chemistry: The crossroads. Elsevier; 2016. [DOI:10.1016/B978-0-444-63688-1.00004-5] [PMID]

37. Habib A, Liang Y, Xu X, Zhu N, Xie J. Immunoinformatic identification of multiple epitopes of gp120 protein of HIV-1 to enhance the immune response against HIV-1 infection. Int J Mole Sci. 2024; 25(4): 2432. [DOI:10.3390/ijms25042432] [PMID] []

38. Zargaran FN, Akya A, Rezaeian S, Ghadiri K, Lorestani RC, Madanchi H, et al. B cell epitopes of four fimbriae antigens of Klebsiella pneumoniae: a comprehensive in silico study for vaccine development. Int J Pept Res Ther. 2021; 27(2): 875-86. [DOI:10.1007/s10989-020-10134-3] [PMID] []

39. Hussein KE, Bahey-El-Din M, Sheweita SA. Immunization with the outer membrane proteins OmpK17 and OmpK36 elicits protection against Klebsiella pneumoniae in the murine infection model. Microb Pathog. 2018; 119: 12-8. [DOI:10.1016/j.micpath.2018.04.004] [PMID]